FOLH1 and neoplasm: Recently, a simplified 3D dosimetry approach following 177Lu-labeled PSMA RLT showed a tumor dose–response relationship with a significant correlation between whole-body tumor-absorbed dose and serum prostate-specific antigen (PSA) decline.